口服抗凝血剂市场－全球产业规模、份额、趋势、机会及预测（按药物类型、适应症、最终用户、地区和竞争格局划分，2021-2031年）

全球口服抗凝血剂（DOAC）市场预计将从 2025 年的 333.6 亿美元成长到 2031 年的 519.2 亿美元，复合年增长率为 7.65%。

这些药物作为特效治疗药物，能够选择性地抑制特定的凝血蛋白（尤其是凝血酶或Xa因子），从而抑制血栓形成。市场快速扩张的主要驱动因素是全球人口老化以及血栓栓塞性疾病（如深层静脉栓塞症和心房颤动）盛行率的不断上升。此外，由于患者和医护人员都更倾向于选择这些新型药物，因为它们具有可预测的药物动力学特性，且监测需求更低，因此临床实践正在逐步淘汰传统的维生素K拮抗剂。根据美国心臟协会（AHA）2024年的数据，心血管疾病将占全球死亡人数的三分之一左右，凸显了对有效预防中风和血栓症管理策略的巨大且持续的需求。

然而，这些强效抗凝血​​药物带来的显着出血风险，阻碍了市场上涨趋势的发展。儘管逆转剂已经研发成功，但其高昂的实施成本以及在新兴国家供应有限，往往阻碍了其广泛应用。这项经济障碍对这些强效抗凝血​​疗法的普及构成了重大挑战。

市场驱动因素

静脉血栓栓塞症和心房颤动的盛行率不断上升，尤其是在全球人口老化背景下，是推动市场成长的主要因素。随着预期寿命的延长，这些血栓栓塞性疾病的发生率显着增加，因此亟需有效的长期抗凝血策略来降低全身性栓塞和中风的风险。这种人口结构的变化正在稳步扩大需要长期治疗性介入的患者群体。美国疾病管制与预防中心 (CDC) 在 2024 年 5 月的一份报告中强调了这些疾病日益加重的负担，并预测到 2030 年，美国将有 1,210 万人患有心房颤动。这项预测凸显了迫切需要可及且有效的治疗方法来应对这群不断扩大且脆弱的患者所带来的风险。

同时，与传统维生素K拮抗剂相比，这些治疗方法具有更优的临床疗效和更方便的使用方式，正推动市场发展。医疗服务提供者和患者越来越倾向于选择这些新型药物，因为它们具有可预测的药物动力学特性，并且无需进行繁琐的常规国际标准化比值（INR）监测。这种临床偏好的广泛转变体现在该类领先药物的商业性成功上。例如，2024年2月，百时美施贵宝公司报告其旗舰口服抗凝血剂的全球销售额达到122亿美元，显示市场对这些先进治疗方案的需求强劲。世界卒中组织估计，到2024年，全球每年将发生超过1,200万例中风，因此，这些药物提供的安全性保障对于有效的预防性抗凝血治疗仍然至关重要。

市场挑战

全球新型口服抗凝血治疗方法（DOAC）市场的成长受到其固有严重出血风险的显着阻碍。尤其是颅内出血和消化道出血等不可控出血的可能性，使得临床医生在为高风险患者群体开立此类药物时犹豫不决。此外，安全管理带来的经济负担也加剧了这种谨慎态度。儘管有逆转剂，但其高昂的购买成本使得许多医疗系统难以负担。因此，在成本受限的环境下，医疗机构往往为了避免处理併发症带来的经济风险而放弃使用这些先进药物。

近期数据显示，抗凝血药物的安全性问题给医疗服务带来了沉重负担，凸显了这项安全隐患的重要性。根据美国疾病管制与预防中心（CDC）2024年的数据，抗凝血药物是导致患者因药物不良反应而就诊急诊室的主要原因，约占此类紧急应变的21%。如此高频率的药物相关急诊需要耗费大量医疗资源进行住院治疗，直接抵消了新型口服抗凝血药物（DOAC）的临床效益。临床安全风险和高成本持续限制DOAC的市场渗透率，尤其是在开发中国家。

市场趋势

随着专利到期，非专利DOAC的上市正在从根本上改变竞争格局。尤其是在欧洲，随着主要品牌药的专利保护期近期结束，这种结构性转变正在加速从高利润品牌药向性价比更高的生物等效替代药的转变，显着影响着老牌製药巨头的收入来源。学名药监管核准的增加导致市场价格普遍下降。这看似矛盾，一方面扩大了对价格敏感地区患者的用药途径，另一方面却挑战了品牌药的商业性优势。此趋势的财务影响已显现：2024年2月，百时美施贵宝公司公布其旗舰抗凝血药物艾乐妥（Eliquis）的国际销售额为9.75亿美元（经外汇调整后下降3%）。这主要是由于平均净售价下降以及学名药在多个欧洲国家的市场份额受到侵蚀。

同时，新一代因子XI抑制剂的临床开发代表着一项突破性进展，旨在将止血与血栓症管理分开。与目前出血风险显着的新型口服抗凝血药物（DOAC）不同，这些新型药物旨在预防病理性血栓形成，同时保留损伤修復所需的凝血机制。这项以安全性为导向的创新满足了高风险族群（包括需要同时接受抗血小板治疗的患者）对安全抗凝血药物的庞大需求。近期试验结果支持了此类药物的临床前景。 2024年11月，Anthos Therapeutics公司报告称，在接受抗血小板治疗的患者中，新型因子XI抑制剂avelacrimab与标准治疗药物利Rivaroxaban相比，出血事件显着减少了67%，凸显了其重新定义安全标准的潜力。

目录

第一章概述

第二章调查方法

第三章执行摘要

第四章：客户评价

5. 全球口服抗凝血剂（DOAC）市场展望

• 市场规模及预测
  • 按金额
• 市占率及预测
  • 依药物类型（Xa因子抑制剂、直接凝血酶抑制剂）
  • 依适应症（心房颤动（AF）、深层静脉栓塞症（DVT）、肺动脉栓塞（PE）、中风预防、其他）
  • 依最终使用者（医院/诊所、门诊手术中心、居家医疗机构、其他）划分
  • 按地区
  • 按公司（2025 年）
• 市场地图

6. 北美口服抗凝血剂（DOAC）市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国家分析
  • 我们
  • 加拿大
  • 墨西哥

7. 欧洲口服抗凝血剂（DOAC）市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国家分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

8. 亚太地区口服抗凝血剂（DOAC）市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

9. 中东和非洲口服抗凝血剂（DOACs）市场展望

• 市场规模及预测
• 市占率及预测
• 中东和非洲：国家分析
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 南非

10. 南美洲口服抗凝血剂（DOAC）市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国家分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章 市场动态

• 司机
• 任务

第十二章 市场趋势与发展

• 併购
• 产品发布
• 最新进展

13. 全球直接口服抗凝血剂（DOAC）市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的可能性
• 供应商电力
• 顾客权力
• 替代品的威胁

第十五章 竞争格局

• Bayer AG
• Boehringer Ingelheim International GmbH
• Bristol Myers Squibb Company
• Pfizer Inc.
• Sanofi
• Zhejiang Huahai Pharmaceutical Co. Ltd.
• Janssen Global Services, LLC
• Aspen Pharmacare Holdings Limited
• Astellas Pharma Inc.
• Lupin Pharmaceutical, Inc.

第十六章 策略建议

第十七章：关于研究公司及免责声明

The Global Direct Oral Anticoagulants (DOACs) Market is projected to expand from USD 33.36 Billion in 2025 to USD 51.92 Billion by 2031, reflecting a CAGR of 7.65%. These pharmaceuticals serve as specialized therapeutic agents that selectively inhibit specific coagulation proteins, notably thrombin or Factor Xa, to mitigate blood clot formation. Rapid market expansion is primarily fueled by an aging global population and the increasing prevalence of thromboembolic disorders such as deep vein thrombosis and atrial fibrillation. Furthermore, the clinical landscape is shifting away from traditional Vitamin K antagonists, as both patients and healthcare providers prefer the predictable pharmacokinetics and reduced monitoring necessities associated with these newer options. Data from the American Heart Association in 2024 indicates that cardiovascular disease was responsible for roughly one in three deaths worldwide, emphasizing the critical and continuous demand for effective stroke prevention and thrombosis management strategies.

However, the market's upward trajectory encounters a significant obstacle regarding the risk of major bleeding events linked to these potent medications. Although reversal agents have been developed, their high acquisition costs and limited availability in emerging economies often discourage widespread implementation. This economic barrier presents a substantial challenge to the universal adoption of these sophisticated anticoagulant therapies.

Market Driver

The escalating prevalence of venous thromboembolism and atrial fibrillation, particularly within an aging global demographic, serves as the primary catalyst for market growth. As life expectancy increases, the incidence of these thromboembolic conditions rises markedly, creating a need for effective long-term anticoagulation strategies to lower the risk of systemic embolism and stroke. This demographic shift generates a consistent and growing patient pool requiring chronic therapeutic intervention. Highlighting the increasing burden of these conditions, the Centers for Disease Control and Prevention projected in a May 2024 report that 12.1 million individuals in the United States will suffer from atrial fibrillation by 2030. This forecast underscores the urgent necessity for accessible and effective treatments to address the risks associated with this expanding vulnerable population.

Concurrently, the market is driven by the superior clinical profile and convenience these therapies offer compared to traditional Vitamin K antagonists. Healthcare providers and patients are increasingly prioritizing these newer agents because they provide predictable pharmacokinetics and eliminate the burdensome requirement for routine International Normalized Ratio monitoring. This broad shift in clinical preference is quantitatively demonstrated by the commercial success of leading drugs in this class. For instance, Bristol Myers Squibb reported in February 2024 that its flagship oral anticoagulant generated worldwide revenues of $12.2 billion, signaling robust demand for these advanced therapeutic options. Given that the World Stroke Organization estimated in 2024 that over 12 million strokes occur globally each year, the safety assurance provided by these medications remains critical for effective preventative anticoagulation.

Market Challenge

The growth of the Global DOACs Market is significantly hindered by the inherent risk of major bleeding events associated with these powerful therapies. The potential for uncontrolled hemorrhaging, specifically intracranial and gastrointestinal bleeding, creates considerable hesitation among clinicians when prescribing for high-risk patient groups. This caution is compounded by the economic burden of safety management; although reversal agents are available, their prohibitive acquisition costs often render them inaccessible within many healthcare systems. Consequently, providers in cost-constrained environments frequently forgo these advanced agents to avoid the financial risks associated with managing potential complications.

The magnitude of this safety concern is underscored by recent data highlighting the strain on healthcare services. According to the Centers for Disease Control and Prevention in 2024, anticoagulants were the leading cause of emergency department visits for adverse drug events, accounting for approximately 21% of these critical encounters. This high frequency of medication-related emergencies necessitates resource-intensive hospitalizations, directly offsetting the perceived clinical advantages of DOACs. The convergence of clinical safety risks and the high cost of emergency reversal therapies continues to restrict market penetration, particularly in developing economies.

Market Trends

The introduction of generic DOAC formulations following patent expirations is fundamentally reshaping the competitive landscape, particularly in European markets where exclusivity periods for major brands have recently concluded. This structural shift is forcing a transition from high-margin branded therapies to cost-effective bioequivalent alternatives, significantly impacting the revenue streams of established pharmaceutical leaders. As regulatory bodies increasingly approve these generic options, the market is experiencing widespread price erosion, which paradoxically expands patient access in cost-sensitive regions while challenging the commercial dominance of originator drugs. The financial implication of this trend is already visible; Bristol Myers Squibb reported in February 2024 that international revenues for its leading anticoagulant Eliquis were $975 million, representing a 3% decrease adjusted for foreign exchange, primarily driven by lower average net selling prices and generic erosion in several European countries.

Simultaneously, the clinical development of next-generation Factor XI inhibitors represents a pivotal advancement aimed at decoupling hemostasis from thrombosis management. Unlike current DOACs that carry a risk of major bleeding, these novel agents are designed to prevent pathologic thrombus formation while sparing the coagulation mechanisms necessary for injury repair. This safety-centric innovation addresses the critical unmet need for anticoagulants that can be safely administered to high-risk populations, such as those requiring concomitant antiplatelet therapy. The clinical promise of this class is substantiated by recent trial results; in November 2024, Anthos Therapeutics reported that the novel Factor XI inhibitor abelacimab demonstrated a substantial 67% reduction in bleeding events for patients on antiplatelet therapy compared to the standard-of-care rivaroxaban, highlighting its potential to redefine safety standards.

Key Market Players

• Bayer AG
• Boehringer Ingelheim International GmbH
• Bristol Myers Squibb Company
• Pfizer Inc.
• Sanofi
• Zhejiang Huahai Pharmaceutical Co. Ltd.
• Janssen Global Services, LLC
• Aspen Pharmacare Holdings Limited
• Astellas Pharma Inc.
• Lupin Pharmaceutical, Inc.

Report Scope

In this report, the Global Direct Oral Anticoagulants (DOACs) Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Direct Oral Anticoagulants (DOACs) Market, By Drug Type

• Factor Xa Inhibitors
• Direct Thrombin Inhibitors

Direct Oral Anticoagulants (DOACs) Market, By Indication

• Atrial Fibrillation (AF)
• Deep Vein Thrombosis (DVT)
• Pulmonary Embolism (PE)
• Stroke Prevention
• Others

Direct Oral Anticoagulants (DOACs) Market, By End User

• Hospitals & Clinics
• Ambulatory Surgical Centers
• Home Care Settings
• Others

Direct Oral Anticoagulants (DOACs) Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Direct Oral Anticoagulants (DOACs) Market.

Available Customizations:

Global Direct Oral Anticoagulants (DOACs) Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Direct Oral Anticoagulants (DOACs) Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Drug Type (Factor Xa Inhibitors, Direct Thrombin Inhibitors)
  • 5.2.2. By Indication (Atrial Fibrillation (AF), Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE), Stroke Prevention, Others)
  • 5.2.3. By End User (Hospitals & Clinics, Ambulatory Surgical Centers, Home Care Settings, Others)
  • 5.2.4. By Region
  • 5.2.5. By Company (2025)
• 5.3. Market Map

6. North America Direct Oral Anticoagulants (DOACs) Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Drug Type
  • 6.2.2. By Indication
  • 6.2.3. By End User
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Direct Oral Anticoagulants (DOACs) Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Drug Type
      • 6.3.1.2.2. By Indication
      • 6.3.1.2.3. By End User
  • 6.3.2. Canada Direct Oral Anticoagulants (DOACs) Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Drug Type
      • 6.3.2.2.2. By Indication
      • 6.3.2.2.3. By End User
  • 6.3.3. Mexico Direct Oral Anticoagulants (DOACs) Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Drug Type
      • 6.3.3.2.2. By Indication
      • 6.3.3.2.3. By End User

7. Europe Direct Oral Anticoagulants (DOACs) Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Drug Type
  • 7.2.2. By Indication
  • 7.2.3. By End User
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Direct Oral Anticoagulants (DOACs) Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Drug Type
      • 7.3.1.2.2. By Indication
      • 7.3.1.2.3. By End User
  • 7.3.2. France Direct Oral Anticoagulants (DOACs) Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Drug Type
      • 7.3.2.2.2. By Indication
      • 7.3.2.2.3. By End User
  • 7.3.3. United Kingdom Direct Oral Anticoagulants (DOACs) Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Drug Type
      • 7.3.3.2.2. By Indication
      • 7.3.3.2.3. By End User
  • 7.3.4. Italy Direct Oral Anticoagulants (DOACs) Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Drug Type
      • 7.3.4.2.2. By Indication
      • 7.3.4.2.3. By End User
  • 7.3.5. Spain Direct Oral Anticoagulants (DOACs) Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Drug Type
      • 7.3.5.2.2. By Indication
      • 7.3.5.2.3. By End User

8. Asia Pacific Direct Oral Anticoagulants (DOACs) Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Drug Type
  • 8.2.2. By Indication
  • 8.2.3. By End User
  • 8.2.4. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Direct Oral Anticoagulants (DOACs) Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Drug Type
      • 8.3.1.2.2. By Indication
      • 8.3.1.2.3. By End User
  • 8.3.2. India Direct Oral Anticoagulants (DOACs) Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Drug Type
      • 8.3.2.2.2. By Indication
      • 8.3.2.2.3. By End User
  • 8.3.3. Japan Direct Oral Anticoagulants (DOACs) Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Drug Type
      • 8.3.3.2.2. By Indication
      • 8.3.3.2.3. By End User
  • 8.3.4. South Korea Direct Oral Anticoagulants (DOACs) Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Drug Type
      • 8.3.4.2.2. By Indication
      • 8.3.4.2.3. By End User
  • 8.3.5. Australia Direct Oral Anticoagulants (DOACs) Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Drug Type
      • 8.3.5.2.2. By Indication
      • 8.3.5.2.3. By End User

9. Middle East & Africa Direct Oral Anticoagulants (DOACs) Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Drug Type
  • 9.2.2. By Indication
  • 9.2.3. By End User
  • 9.2.4. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Direct Oral Anticoagulants (DOACs) Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Drug Type
      • 9.3.1.2.2. By Indication
      • 9.3.1.2.3. By End User
  • 9.3.2. UAE Direct Oral Anticoagulants (DOACs) Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Drug Type
      • 9.3.2.2.2. By Indication
      • 9.3.2.2.3. By End User
  • 9.3.3. South Africa Direct Oral Anticoagulants (DOACs) Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Drug Type
      • 9.3.3.2.2. By Indication
      • 9.3.3.2.3. By End User

10. South America Direct Oral Anticoagulants (DOACs) Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Drug Type
  • 10.2.2. By Indication
  • 10.2.3. By End User
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Direct Oral Anticoagulants (DOACs) Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Drug Type
      • 10.3.1.2.2. By Indication
      • 10.3.1.2.3. By End User
  • 10.3.2. Colombia Direct Oral Anticoagulants (DOACs) Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Drug Type
      • 10.3.2.2.2. By Indication
      • 10.3.2.2.3. By End User
  • 10.3.3. Argentina Direct Oral Anticoagulants (DOACs) Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Drug Type
      • 10.3.3.2.2. By Indication
      • 10.3.3.2.3. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Direct Oral Anticoagulants (DOACs) Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Bayer AG
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Boehringer Ingelheim International GmbH
• 15.3. Bristol Myers Squibb Company
• 15.4. Pfizer Inc.
• 15.5. Sanofi
• 15.6. Zhejiang Huahai Pharmaceutical Co. Ltd.
• 15.7. Janssen Global Services, LLC
• 15.8. Aspen Pharmacare Holdings Limited
• 15.9. Astellas Pharma Inc.
• 15.10. Lupin Pharmaceutical, Inc.

16. Strategic Recommendations

17. About Us & Disclaimer